Silver Health Bio Research Center established in 2015 is an affiliated organization of Integrated Aging Research Institute at GIST. At the center, nearly 90 full-time researchers, including 14 faculty members at GIST, conduct various aging-related research projects, focusing on molecular mechanisms of biological aging and pathophysiology of geriatric disorders, with multidisciplinary approaches. This way, we hope to solve problems and challenges related super aged society by developing fundamental technologies that can readily be applied for silver industry.
The Silver Health Bio Research Center aims to develop social skills to cope with the aging and to develop original technology for the aging-related industry through comprehensive interdisciplinary research on the aging phenomenon of life. In addition, the systematic and specialized research capacity and the aging research group are being integrated to grow into a specialized research institute for the control of aging and geriatric diseases.
No. | Research Topics | Research Information |
---|---|---|
1 | Basic research on aging |
|
2 | Basic research on geriatric diseases |
|
3 | Multi- and inter-disciplinary research on biological aging and related diseases |
|
4 | Establishment of animal models for geriatric disorders |
|
The Silver Health Bio Research Center will identify various social problems caused by population aging through basic research on aging and geriatric diseases, and will identify various solutions for maintaining national competitiveness. We will provide the basis for the world best research center for aging and geriatric disease through the selection and intensive support policy for excellence in the previous year. In addition, through practical joint research between basic research on aging and applied research, we will build a practical technology development system for solving social problems due to the entry of aging society. Therefore, it is expected to create a new paradigm of the aging research industry utilizing original technology and convergence technology for degenerative disease and to open up a new market.